Literature DB >> 14692019

STK15/Aurora-A expression in primary breast tumors is correlated with nuclear grade but not with prognosis.

Melanie E Royce1, Weiya Xia, Aysegul A Sahin, Hiroshi Katayama, Dennis A Johnston, Gabriel Hortobagyi, Subrata Sen, Mien-Chie Hung.   

Abstract

BACKGROUND: DNA amplification on chromosome 20q13 is commonly detected in breast carcinoma and is correlated with poor prognosis. STK15 maps to this amplicon. The objective of the current study was to use immunohistochemistry to determine STK15 expression in primary breast tumors. The authors also explored whether STK15 was a prognostic factor for breast carcinoma by comparing the level of STK15 gene expression with clinical parameters that are known prognostic factors for the disease.
METHODS: Archival mastectomy and lumpectomy specimens, randomly selected, were immunohistochemically stained to determine the STK15 gene expression level. The clinical parameters of these same patients were reviewed retrospectively and analyzed for correlations with STK15 expression level, based on a positive-versus-negative scoring system.
RESULTS: Of the 112 human breast tumor specimens analyzed, 26% stained positively for STK15 by immunohistochemistry. Of the tumors, that stained positively 62.1% had a well-to-moderately differentiated nuclear grade. The correlation between STK15 staining and nuclear grade was nearly statistically significant (P = 0.05). No association was found between STK15 staining and tumor size, lymph node status, or hormone receptor status. Analysis of recurrence-free survival and overall survival rates also failed to reveal a statistically significant difference between the two groups.
CONCLUSIONS: STK15 expression by immunohistochemistry was noted in approximately one-fourth of primary breast tumors. STK15 expression was associated with nuclear grade, but no correlation was found between the other clinical parameters evaluated. Furthermore, no differences were found in survival rates when they were analyzed by level of STK15 staining. Copyright 2003 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14692019     DOI: 10.1002/cncr.11879

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  20 in total

1.  Structural studies of B-type Aurora kinase inhibitors using computational methods.

Authors:  Mm Neaz; M Muddassar; Fa Pasha; Seung Joo Cho
Journal:  Acta Pharmacol Sin       Date:  2010-02       Impact factor: 6.150

2.  Prognostic value of proliferation markers expression in breast cancer.

Authors:  Natalija Dedić Plavetić; Jasminka Jakić-Razumović; Ana Kulić; Damir Vrbanec
Journal:  Med Oncol       Date:  2013-03-07       Impact factor: 3.064

3.  Elevated Aurora B expression contributes to chemoresistance and poor prognosis in breast cancer.

Authors:  Yiqian Zhang; Chunling Jiang; Huilan Li; Feng Lv; Xiaoyan Li; Xiaolong Qian; Li Fu; Bo Xu; Xiaojing Guo
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

4.  Aurora-A is an efficient marker for predicting poor prognosis in human nasopharyngeal carcinoma with aggressive local invasion: 208 cases with a 10-year follow-up from a single institution.

Authors:  Zhi-Gang Liu; Wei Yi; Ya-Lan Tao; Hsiao Chang Chan; Mu-Sheng Zeng; Yun-Fei Xia
Journal:  Oncol Lett       Date:  2012-03-27       Impact factor: 2.967

5.  Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen.

Authors:  John McLaughlin; Vadim Markovtsov; Hui Li; Steve Wong; Marina Gelman; Yanhong Zhu; Christian Franci; D Wayne Lang; Erlina Pali; Joe Lasaga; Caroline Low; Feifei Zhao; Betty Chang; Tarikere L Gururaja; Weiduan Xu; Muhammad Baluom; David Sweeny; David Carroll; Arvinder Sran; Sambaiah Thota; Manjeet Parmer; Angela Romane; George Clemens; Elliott Grossbard; Kunbin Qu; Yonchu Jenkins; Taisei Kinoshita; Vanessa Taylor; Sacha J Holland; Ankush Argade; Rajinder Singh; Polly Pine; Donald G Payan; Yasumichi Hitoshi
Journal:  J Cancer Res Clin Oncol       Date:  2010-01       Impact factor: 4.553

6.  Reduced level of the spindle checkpoint protein BUB1B is associated with aneuploidy in colorectal cancers.

Authors:  E Burum-Auensen; P M DeAngelis; A R Schjølberg; J Røislien; O Mjåland; O P F Clausen
Journal:  Cell Prolif       Date:  2008-08       Impact factor: 6.831

7.  Expression of Aurora A (but not Aurora B) is predictive of survival in breast cancer.

Authors:  Yasmine Nadler; Robert L Camp; Candice Schwartz; David L Rimm; Harriet M Kluger; Yuval Kluger
Journal:  Clin Cancer Res       Date:  2008-07-15       Impact factor: 12.531

8.  Aurora A is a negative prognostic factor and a new therapeutic target in human neuroblastoma.

Authors:  Xiaoying Shang; Susan M Burlingame; M Fatih Okcu; Ningling Ge; Heidi V Russell; Rachel A Egler; Rodney D David; Sanjeev A Vasudevan; Jianhua Yang; Jed G Nuchtern
Journal:  Mol Cancer Ther       Date:  2009-08-11       Impact factor: 6.261

9.  Aurora-A is a novel predictor of poor prognosis in patients with resected lung adenocarcinoma.

Authors:  Bo Zeng; Yiyan Lei; Haoshuai Zhu; Shenyuan Luo; Mei Zhuang; Chunhua Su; Jianyong Zou; Lei Yang; Honghe Luo
Journal:  Chin J Cancer Res       Date:  2014-04       Impact factor: 5.087

10.  Aurora-A expression is independently associated with chromosomal instability in colorectal cancer.

Authors:  Yoshifumi Baba; Katsuhiko Nosho; Kaori Shima; Natsumi Irahara; Shoko Kure; Saori Toyoda; Gregory J Kirkner; Ajay Goel; Charles S Fuchs; Shuji Ogino
Journal:  Neoplasia       Date:  2009-05       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.